Director, President and CEO · Janux Therapeutics, Inc. · Janux Therapeutics, Inc. — Stock option (right to buy)
Side
A
Value
—
Shares
338.1K
Price
—
Executed
Jan 2, 2026
Disclosed
Jan 2, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jan 2 executedJan 2, 2026 disclosed
JANX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Janux Therapeutics, Inc. — Stock option (right to buy)
Ticker
JANX
Shares
338.1K
Price per share
$0
Execution date (reported)
Jan 2, 2026
Owned after transaction
338.1K shares
Days from execution to publication
0
What this establishes
Campbell David Alan filed this Form 4 reporting a grant or award of JANX on Jan 2, 2026. It became public on Jan 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, President and CEO
Campbell David Alancik:0001864158
Issuer
Janux Therapeutics, Inc.cik:0001817713
Revision history · 0
No field has changed since this record was first ingested.
